Since 2015 we have been proud to partner and support clients who are at the forefront of creating groundbreaking new treatments and therapies.
We carefully select and recruit the highest calibre of personnel. Every member of
our team is an expert in their field and passionate about access for Rare Diseases.
As global experts in access for orphan drug, cell and gene therapy,
we truly understand the complexity and challenges of the market
access environment. P4A solutions are designed to be bespoke
to your situation, location and needs. One size does not fit all.
Our 2-minute promotional video will give you a thorough overview
into P4A and our tailored, meticulous and innovative approach.
We are an award-winning global consultancy and recognised
for excellence in access for orphan drugs & ATMPs.
Written by Andrea Bernardini, Associate Consultant & Marco Sancandi, Analyst Contacts: [email protected]; [email protected] In a significant step forward for healthcare in Italy, the National Rare
Written by: James Lee, Analyst Contact: [email protected] China, with 1.4 billion people, holds promise as a market for pharmaceutical companies due to its major overhaul of
Written by: Angeliki Meletsi; Analyst Contact: [email protected] The European Commission proposals on the EU pharmaceutical legislation revision, announced in April 2023, have not included any
